Nutraland USA touts study of AKK001 postbiotic and tributyrin in metabolic health

Nutraland USA announced a peer-reviewed clinical study on AKK001™, a pasteurized Akkermansia muciniphila postbiotic, paired with tributyrin in adults with overweight or obesity. The randomized trial found improvements in body composition and several metabolic markers over 90 days, while reporting no significant differences in liver, kidney or thyroid safety measures.

Why it matters: - The study adds to the clinical evidence base for pasteurized Akkermansia muciniphila, a postbiotic category drawing interest in microbiome-focused nutrition. - The results could support future finished-product development around metabolic health, though the study tested AKK001™ together with tributyrin. - The findings matter for dietary supplement, functional food and beverage makers looking for stable, non-viable ingredients with formulation flexibility.

What happened: - Nutraland USA announced the publication of a peer-reviewed clinical trial in Alternative Therapies in Health and Medicine. - The randomized, placebo-controlled study evaluated AKK001™, a pasteurized Akkermansia muciniphila postbiotic, plus tributyrin in 60 otherwise healthy adults with overweight or obesity. - Participants received either placebo or one capsule daily containing 1.5 × 10¹⁰ TFU of pasteurized AKK001™ plus 150 mg of butyrate as tributyrin for 90 days.

The details: - The study measured body morphology, glucose regulation, lipid metabolism and selected safety parameters. - At 90 days, the treatment group showed lower mean body weight than placebo, at 75.3 kg versus 82.5 kg. - The treatment group also showed lower body fat percentage than placebo, at 25.6% versus 29.8%. - Reported outcomes included lower waist circumference and lower ultrasound-measured abdominal fat thickness compared with placebo. - The treatment group showed favorable differences in glucose and lipid measures, including total cholesterol of 166.3 mg/dL versus 189.5 mg/dL for placebo. - The treatment group also had a higher estimated basal metabolic rate than placebo at 90 days. - No significant differences were seen between groups in liver, kidney or thyroid function parameters after one or three months. - The study was funded by Youthorin Biotechnology Co., Ltd., which supplied the AKK001™ and butyrate study material. - Nutraland USA is the exclusive North American distributor of AKK001™. - The full manuscript is available here. - Nutraland USA also directs technical and commercial inquiries to its website or sales@nutralandusa.com.

Between the lines: - The trial’s positive findings are tied to a combination product, not AKK001™ alone, so the individual contribution of the postbiotic remains unclear. - The company is positioning AKK001™ as both a clinical ingredient and a formulation-friendly option because it contains no viable bacteria. - Dr. Gene Bruno, Nutraland USA’s chief scientific officer and primary author, said the breadth of outcomes provides a foundation for continued research into postbiotics and metabolic health.

What's next: - Further studies will be needed to separate AKK001™ effects from tributyrin effects and to clarify mechanisms behind the observed changes. - Nutraland USA is likely to use the publication to support commercial conversations with supplement and food manufacturers. - The company’s next step is broader technical and commercial deployment of AKK001™ in finished-product development.

The bottom line: - Nutraland USA now has a peer-reviewed human study suggesting its AKK001™ plus tributyrin combo may improve body composition and metabolic markers over 90 days, with no major safety signals reported.